Movement Alert｜DUALITYBIO-B Rises 5.32% in Regular Trading, DB-1311 Combo First-Line SCLC ORR of 92.3% Continues to Drive Momentum

Market Focus09-21

On September 21, DUALITYBIO-B rose 5.32% in regular trading, trading at HK$210.4/share, with turnover of HK$29.10 million. The stock has gained meaningfully over recent sessions, extending a multi-day rally fueled by landmark clinical readouts.

On the news front, the World Conference on Lung Cancer (WCLC) recently disclosed updated Ib/II data for B7-H3 ADC DB-1311/BNT324 — co-developed with BioNTech — in combination with PD-L1×VEGF-A bispecific antibody Pumitamig in advanced lung cancer. Among 71 evaluable small cell lung cancer patients, the overall objective response rate reached 70.4%, with first-line ORR hitting 92.3%, second-line 77.3%, and third-line-plus 52.4%. UBS previously noted DB-1311 as the primary valuation driver, projecting peak sales of RMB 38.3 billion, above market consensus of RMB 28.6 billion.

The momentum is further underpinned by a collaboration with Genentech on next-generation ADC development via the DUPAC platform, carrying over US$1 billion in potential milestone payments, as well as consecutive insider purchases by Chairman and CEO Zhu Zhongyuan totaling approximately HK$3.58 million in early September.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173156900?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-21 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173156900","market":"hk","top_or_hot":-1,"title":"Movement Alert｜DUALITYBIO-B Rises 5.32% in Regular Trading, DB-1311 Combo First-Line SCLC ORR of 92.3% Continues to Drive Momentum","media":"Market Focus","content":"<p><p>On September 21, DUALITYBIO-B rose 5.32% in regular trading, trading at HK$210.4/share, with turnover of HK$29.10 million. The stock has gained meaningfully over recent sessions, extending a multi-day rally fueled by landmark clinical readouts.</p><p>On the news front, the World Conference on Lung Cancer (WCLC) recently disclosed updated Ib/II data for B7-H3 ADC DB-1311/BNT324 — co-developed with BioNTech — in combination with PD-L1×VEGF-A bispecific antibody Pumitamig in advanced lung cancer. Among 71 evaluable small cell lung cancer patients, the overall objective response rate reached 70.4%, with first-line ORR hitting 92.3%, second-line 77.3%, and third-line-plus 52.4%. UBS previously noted DB-1311 as the primary valuation driver, projecting peak sales of RMB 38.3 billion, above market consensus of RMB 28.6 billion.</p><p>The momentum is further underpinned by a collaboration with Genentech on next-generation ADC development via the DUPAC platform, carrying over US$1 billion in potential milestone payments, as well as consecutive insider purchases by Chairman and CEO Zhu Zhongyuan totaling approximately HK$3.58 million in early September.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DUALITYBIO-B Rises 5.32% in Regular Trading, DB-1311 Combo First-Line SCLC ORR of 92.3% Continues to Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DUALITYBIO-B Rises 5.32% in Regular Trading, DB-1311 Combo First-Line SCLC ORR of 92.3% Continues to Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-21 09:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 21, DUALITYBIO-B rose 5.32% in regular trading, trading at HK$210.4/share, with turnover of HK$29.10 million. The stock has gained meaningfully over recent sessions, extending a multi-day rally fueled by landmark clinical readouts.</p><p>On the news front, the World Conference on Lung Cancer (WCLC) recently disclosed updated Ib/II data for B7-H3 ADC DB-1311/BNT324 — co-developed with BioNTech — in combination with PD-L1×VEGF-A bispecific antibody Pumitamig in advanced lung cancer. Among 71 evaluable small cell lung cancer patients, the overall objective response rate reached 70.4%, with first-line ORR hitting 92.3%, second-line 77.3%, and third-line-plus 52.4%. UBS previously noted DB-1311 as the primary valuation driver, projecting peak sales of RMB 38.3 billion, above market consensus of RMB 28.6 billion.</p><p>The momentum is further underpinned by a collaboration with Genentech on next-generation ADC development via the DUPAC platform, carrying over US$1 billion in potential milestone payments, as well as consecutive insider purchases by Chairman and CEO Zhu Zhongyuan totaling approximately HK$3.58 million in early September.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1173156900","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173156900","pubTimestamp":1789955054,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 21, DUALITYBIO-B rose 5.32% in regular trading, trading at HK$210.4/share, with turnover of HK$29.10 million. The stock has gained meaningfully over recent sessions, extending a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"走势提醒|DUALITYBIO-B常规交易上涨5.32%，DB-1311 Combo一线SCLC ORR 92.3%继续推动势头","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On September 21, DUALITYBIO-B rose 5.32% in regular trading, trading at HK$210.4/share, with turnover of HK$29.10 million. The stock has gained meaningfully over recent sessions, extending a multi-day rally fueled by landmark clinical readouts.On the news front, the World Conference on Lung Cancer (WCLC) recently disclosed updated Ib/II data for B7-H3 ADC DB-1311/BNT324 — co-developed with BioNTech — in combination with PD-L1×VEGF-A bispecific antibody Pumitamig in advanced lung cancer. Among 71 evaluable small cell lung cancer patients, the overall objective response rate reached 70.4%, with first-line ORR hitting 92.3%, second-line 77.3%, and third-line-plus 52.4%. UBS previously noted DB-1311 as the primary valuation driver, projecting peak sales of RMB 38.3 billion, above market consensus of RMB 28.6 billion.The momentum is further underpinned by a collaboration with Genentech on next-generation ADC development via the DUPAC platform, carrying over US$1 billion in potential milestone payments, as well as consecutive insider purchases by Chairman and CEO Zhu Zhongyuan totaling approximately HK$3.58 million in early September.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173156900","isCrawlerRequest":true}